Kiora Pharmaceuticals (KPRX) Stock Forecast, Price Target & Predictions
KPRX Stock Forecast
Kiora Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
KPRX Analyst Ratings
According to 1 Wall Street analysts, Kiora Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KPRX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 09, 2023 | Maxim Group | - | Buy | Upgrade |
Kiora Pharmaceuticals's last stock rating was published by Maxim Group on Feb 09, 2023. The company Upgrade its KPRX rating from "null" to "Buy".
Kiora Pharmaceuticals Financial Forecast
Kiora Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | $15.00K | $14.00K | $13.00K | $12.50K | $507.67K | $10.50K | $20.00K | $16.00M |
| High Forecast | $15.00K | $14.00K | $13.00K | $12.50K | $507.67K | $10.50K | $20.00K | $16.00M |
| Low Forecast | $15.00K | $14.00K | $13.00K | $12.50K | $507.67K | $10.50K | $20.00K | $16.00M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - |
Kiora Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KPRX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Kiora Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | $3.00K | $2.80K | $2.60K | $2.50K | $101.53K | $2.10K | $4.00K | $3.20M |
| High Forecast | $3.00K | $2.80K | $2.60K | $2.50K | $101.53K | $2.10K | $4.00K | $3.20M |
| Low Forecast | $3.00K | $2.80K | $2.60K | $2.50K | $101.53K | $2.10K | $4.00K | $3.20M |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict KPRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kiora Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Kiora Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-2.25M | $-2.21M | $-2.25M | $-2.94M | $-2.67M | $-3.18M | $-3.57M | $10.32M |
| High Forecast | $-2.25M | $-2.21M | $-2.25M | $-2.94M | $-2.67M | $-3.18M | $-3.57M | $10.32M |
| Low Forecast | $-2.25M | $-2.21M | $-2.25M | $-2.94M | $-2.67M | $-3.18M | $-3.57M | $10.32M |
| Surprise % | - | - | - | - | - | - | - | - |
Kiora Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KPRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kiora Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.17M | $1.09M | $1.02M | $977.43K | $39.70M | $821.04K | $1.56M | $1.25B |
| High Forecast | $1.17M | $1.09M | $1.02M | $977.43K | $39.70M | $821.04K | $1.56M | $1.25B |
| Low Forecast | $1.17M | $1.09M | $1.02M | $977.43K | $39.70M | $821.04K | $1.56M | $1.25B |
| Surprise % | - | - | - | - | - | - | - | - |
Kiora Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to KPRX last annual SG&A of $NaN (undefined).
Kiora Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.54 | $-0.53 | $-0.54 | $-0.70 | $-0.64 | $-0.76 | $-0.86 | $2.48 |
| High Forecast | $-0.54 | $-0.53 | $-0.54 | $-0.70 | $-0.64 | $-0.76 | $-0.86 | $2.48 |
| Low Forecast | $-0.54 | $-0.53 | $-0.54 | $-0.70 | $-0.64 | $-0.76 | $-0.86 | $2.48 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Kiora Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KPRX previous annual EPS of $NaN (undefined).
KPRX Forecast FAQ
Is Kiora Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Kiora Pharmaceuticals (KPRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of KPRX's total ratings.
What are Kiora Pharmaceuticals's analysts' financial forecasts?
Kiora Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $16.54M (high $16.54M, low $16.54M), average EBITDA is $3.31M (high $3.31M, low $3.31M), average net income is $896.68K (high $896.68K, low $896.68K), average SG&A $1.29B (high $1.29B, low $1.29B), and average EPS is $0.215 (high $0.215, low $0.215). KPRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $54.5K (high $54.5K, low $54.5K), average EBITDA is $10.9K (high $10.9K, low $10.9K), average net income is $-9.655M (high $-9.655M, low $-9.655M), average SG&A $4.26M (high $4.26M, low $4.26M), and average EPS is $-2.315 (high $-2.315, low $-2.315).